The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 18, 2023
Filed:
May. 13, 2021
Applicant:
Gilead Sciences, Inc., Foster City, CA (US);
Inventors:
Barton W. Phillips, San Mateo, CA (US);
Doris T. Tang, Burlingame, CA (US);
Chandrasekar Venkataramani, San Carlos, CA (US);
Kin S. Yang, San Mateo, CA (US);
Anna Zagorska, Foster City, CA (US);
Assignee:
Gilead Sciences, Inc., Foster City, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 498/04 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 413/04 (2006.01); C07D 413/14 (2006.01); C07D 403/10 (2006.01); C07D 401/10 (2006.01); C07D 413/10 (2006.01);
U.S. Cl.
CPC ...
C07D 403/10 (2013.01); C07D 401/10 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 413/04 (2013.01); C07D 413/10 (2013.01); C07D 413/14 (2013.01); C07D 498/04 (2013.01);
Abstract
The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non alcoholic steatohepatitis (NASH).